

# VU Research Portal

## Towards primary prevention of rheumatoid arthritis

Bos, W.H.

2009

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Bos, W. H. (2009). *Towards primary prevention of rheumatoid arthritis: autoantibodies in the (pre) clinical phase*. s.n.

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

---

# Table of contents

<b>Chapter 1</b> .....	<b>6</b>
General introduction: what precedes rheumatoid arthritis and can we prevent or delay disease onset by targeting in the preclinical phase?	
<b>Chapter 2</b> .....	<b>20</b>
IgM-RF, anti-CCP and ACF antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis <i>Journal of Rheumatology 2008; 35:425–8</i>	
<b>Chapter 3</b> .....	<b>28</b>
Differential response of the rheumatoid factor and anti-citrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis <i>Journal of Rheumatology 2008; 35:1972–77</i>	
<b>Chapter 4</b> .....	<b>40</b>
The IgG4 subclass of anti-citrullinated protein antibodies preferentially decreases during treatment with TNF blocking agents in patients with rheumatoid arthritis <i>Annals of the Rheumatic Diseases 2009; 68: 558-63</i>	
<b>Chapter 5</b> .....	<b>52</b>
Duration of pre-rheumatoid arthritis anti-CCP positivity is positively associated with age at seroconversion <i>Annals of the Rheumatic Diseases 2008; 67: 1642-3</i>	
<b>Chapter 6</b> .....	<b>56</b>
The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels <i>Annals of the Rheumatic Diseases 2008; 67:1347-50</i>	
<b>Chapter 7</b> .....	<b>66</b>
Arthritis development in arthralgia patients is strongly associated with ACPA status: a prospective cohort study <i>Submitted for publication</i>	
<b>Chapter 8</b> .....	<b>78</b>
Gene expression profiling in arthralgia patients predicts development of arthritis independent of autoantibody status <i>Submitted for publication</i>	
<b>Chapter 9</b> .....	<b>104</b>
Dexamethasone in the primary prevention of rheumatoid arthritis: a randomized trial <i>Submitted for publication</i>	
<b>Chapter 10</b> .....	<b>118</b>
Summary and Discussion	
<b>Chapter 11</b> .....	<b>126</b>
Samenvatting Lijst van Publicaties Dankwoord Curriculum Vitae	